+171.7%
SLV vs MRNA
+27.9%
+143.8%
-52.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -5.3% | +0.7% | -6.0% | -5.3% |
| 7D | -5.0% | -8.2% | +3.2% | -4.7% |
| 30D | -1.8% | +125.6% | -127.4% | -9.7% |
| 3M | -0.3% | +197.1% | -197.3% | -11.4% |
| 6M | -28.2% | +148.5% | -176.7% | -35.2% |
| YTD | -10.7% | +363.3% | -374.0% | -23.0% |
| 1Y | +53.7% | +462.0% | -408.3% | +30.8% |
| All | +171.7% | +27.9% | +143.8% | +122.2% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling